MicroRNA binding site polymorphisms as biomarkers of cancer risk

Expert Review of Molecular Diagnostics

Volumn 10, Issue 6, 2010, Pages 817-829

  Pelletier, Cory ^a   Weidhaas, Joanne B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 UTR; cancer; miRNA; miRNA binding site; SNP

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

3' UNTRANSLATED REGION; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LUNG CARCINOMA; MOUTH CANCER; OVARY CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; THYROID PAPILLARY CARCINOMA;

3' UNTRANSLATED REGIONS; BINDING SITES; BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; MUTATION; NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77956763087     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.59     Document Type: Review

References (119)

1. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 29(7), 1306-1311 (2008).
2. Medina PP, Slack FJ. MicroRNAs and cancer: an overview. Cell Cycle 7(16), 2485-2492 (2008).
3. Chang TC, Mendell JT. MicroRNAs in vertebrate physiology and human disease. Annu. Rev. Genomics. Hum. Genet. 8, 215-239 (2007).
4. Sheng Y, Engstrom PG, Lenhard B. Mammalian microRNA prediction through a support vector machine model of sequence and structure. PloS ONE 2(9), e946 (2007).
5. Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol. Biol. 342, 129-138 (2006).
6. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development 132(21), 4653-4662 (2005).
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004).
8. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27(34), 5848-5856 (2009).
9. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 115(2), 209-216 (2003).
10. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115(2), 199-208 (2003).
11. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 18(5), 504-511 (2004).
12. Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ. The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3′UTR. Genes Dev. 18(2), 132-137 (2004).
13. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 3(3), e85 (2005).
14. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 136(2), 215-233 (2009).
15. Steitz JA, Vasudevan S. miRNPs: versatile regulators of gene expression in vertebrate cells. Biochem. Soc. Trans. 37(Pt 5), 931-935 (2009).
16. Richter JD. Think you know how miRNAs work? Think again. Nat. Struct. Mol. Biol. 15(4), 334-336 (2008).
17. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9(2), 102-114 (2008).
18. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol. 2(11), e363 (2004).
19. Maragkakis M, Reczko M, Simossis VA et al. DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res. 37(Web Server issue), W273-W276 (2009).
20. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 10(10), 1507-1517 (2004).
21. Rusinov V, Baev V, Minkov IN, Tabler M. MicroInspector: a web tool for detection of miRNA binding sites in an RNA sequence. Nucleic Acids Res. 33(Web Server issue), W696-W700 (2005).
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1), 15-20 (2005).
23. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 115(7), 787-798 (2003).
24. Li L, Xu J, Yang D, Tan X, Wang H. Computational approaches for microRNA studies: a review. Mamm. Genome 21(1-2), 1-12 (2009).
25. Rajewsky N. microRNA target predictions in animals. Nat. Genet. 38(Suppl.), S8-S13 (2006).
26. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat. Genet. 39(10), 1278-1284 (2007).
27. Thadani R, Tammi MT. MicroTar: predicting microRNA targets from RNA duplexes. BMC Bioinform. 7(Suppl. 5), S20 (2006).
28. Miranda KC, Huynh T, Tay Y et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126(6), 1203-1217 (2006).
29. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 455(7209), 64-71 (2008).
30. Selbach M, Schwanhausser B, Thierfelder N et al. Widespread changes in protein synthesis induced by microRNAs. Nature 455, 58-63 (2008).
31. Petrelli NJ, Winer EP, Brahmer J et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening -a report from the American Society of Clinical Oncology. J. Clin. Oncol. 27(35), 6052-6069 (2009).
32. Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: tools for cancer diagnostics. Gut 58(11), 1546-1554 (2009).
33. Liu CG, Calin GA, Meloon B et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl Acad. Sci. USA 101(26), 9740-9744 (2004).
34. Esquela-Kerscher A, Slack FJ. Oncomirs -microRNAs with a role in cancer. Nat. Rev. Cancer 6(4), 259-269 (2006).
35. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005).
36. Klein U, Lia M, Crespo M et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17(1), 28-40 (2010).
37. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat. Rev. Cancer 4(11), 850-860 (2004).
38. Yu Z, Li Z, Jolicoeur N et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res. 35(13), 4535-4541 (2007).
39. He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA 102(52), 19075-19080 (2005).
40. Melillo RM, Castellone MD, Guarino V et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115(4), 1068-1081 (2005).
41. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63(7), 1454-1457 (2003).
42. Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr. Pathol. 20(2), 85-91 (2009).
43. Felli N, Fontana L, Pelosi E et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl Acad. Sci. USA 102(50), 18081-18086 (2005).
44. Natali PG, Berlingieri MT, Nicotra MR et al. Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res. 55(8), 1787-1791 (1995).
45. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
46. Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Ashkenazi Jews. Fam. Cancer 3(3-4), 259-264 (2004).
47. Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Breast cancer risks for BRCA1/2 carriers. Science 306(5705), 2187-2191; author reply 2187-2191 (2004).
48. Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E. SNPs in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high risk women. Int. J. Cancer (2009).
49. Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065-7070 (2005).
50. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin. Chem. 55(4), 623-631 (2009).
51. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-a (ERa) and represses ERa messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 21(5), 1132-1147 (2007).
52. Brendle A, Lei H, Brandt A et al. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 29(7), 1394-1399 (2008).
53. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 25(46), 6170-6175 (2006).
54. Tchatchou S, Jung A, Hemminki K et al. A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis 30(1), 59-64 (2009).
55. Saetrom P, Biesinger J, Li SM et al. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res. 69(18), 7459-7465 (2009).
56. Blenkiron C, Goldstein LD, Thorne NP et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 8(10), R214 (2007).
57. Mattie MD, Benz CC, Bowers J et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 5, 24 (2006).
58. Song F, Zheng H, Liu B et al. An miR-502-binding site single-nucleotide polymorphism in the 3′-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin. Cancer Res. 15(19), 6292-6300 (2009).
59. van Hest LP, Ruijs MW, Wagner A et al. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family. Fam. Cancer 6(3), 311-316 (2007).
60. Tabori U, Nanda S, Druker H, Lees J, Malkin D. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res. 67(4), 1415-1418 (2007).
61. Pongsavee M, Yamkamon V, Dakeng S et al. The BRCA1 3′-UTR: 5711+421T/T-5711+1286T/T genotype is a possible breast and ovarian cancer risk factor. Genet. Test. Mol. Biomarkers 13(3), 307-317 (2009).
62. Nicoloso MS, Sun H, Spizzo R et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 70(7), 2789-2798 (2010).
63. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 30(4), 460-471 (2008).
64. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 318(5858), 1931-1934 (2007).
65. Peto R. Influence of dose and duration of smoking on lung cancer rates. IARC Sci. Publ. (74), 23-33 (1986).
66. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 123(Suppl. 1), 21S-49S (2003).
67. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005).
68. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101(9), 2999-3004 (2004).
69. Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64(11), 3753-3756 (2004).
70. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006).
71. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 52(Suppl. 9), 2665S-2669S (1992).
72. Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK. Genetic pathways and mutation profiles of human cancers: site-and exposure-specific patterns. Carcinogenesis 28(9), 1851-1858 (2007).
73. Hoa M, Davis SL, Ames SJ, Spanjaard RA. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res. 62(24), 7154-7156 (2002).
74. Chin LJ, Ratner E, Leng S et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 68(20), 8535-8540 (2008).
75. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J. Natl Cancer Inst. 91(23), 2032-2038 (1999).
76. Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, Kelsey KT. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 69(1), 51-53 (2009).
77. Christensen BC, Moyer BJ, Avissar M et al. A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 30(6), 1003-1007 (2009).
78. Graziano F, Canestrari E, Loupakis F et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. DOI:10.1038/tpj.2010.9. (2010) (Epub ahead of print).
79. Liu X, Chen Z, Yu J, Xia J, Zhou X. MicroRNA profiling and head and neck cancer. Comp. Funct. Genomics 837514 (2009).
80. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10-30 (2005).
81. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
82. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106-130 (2006).
83. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
84. Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 48(11), 3282-3287 (1988).
85. Furniss CS, McClean MD, Smith JF et al. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int. J. Cancer 120(11), 2386-2392 (2007).
86. Ng SK, Kabat GC, Wynder EL. Oral cavity cancer in non-users of tobacco. J. Natl Cancer Inst. 85(9), 743-745 (1993).
87. Tran N, McLean T, Zhang X et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem. Biophys. Res. Commun. 358(1), 12-17 (2007).
88. Chang SS, Jiang WW, Smith I et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int. J. Cancer 123(12), 2791-2797 (2008).
89. Ramdas L, Giri U, Ashorn CL et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 31(5), 642-654 (2009).
90. Potter JD. Colorectal cancer: molecules and populations. J. Natl Cancer Inst. 91(11), 916-932 (1999).
91. Aslam MI, Taylor K, Pringle JH, Jameson JS. MicroRNAs are novel biomarkers of colorectal cancer. Br. J. Surg. 96(7), 702-710 (2009).
92. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 37(Web Server issue), W600-W605 (2009).
93. Zhang W, Dahlberg JE, Tam W. MicroRNAs in tumorigenesis: a primer. Am. J. Pathol. 171(3), 728-738 (2007).
94. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103(7), 2257-2261 (2006).
95. Cummins JM, He Y, Leary RJ et al. The colorectal microRNAome. Proc. Natl Acad. Sci. USA 103(10), 3687-3692 (2006).
96. Xi Y, Formentini A, Chien M et al. Prognostic values of microRNAs in colorectal cancer. Biomark. Insights 2, 113-121 (2006).
97. Asangani IA, Rasheed SA, Nikolova DA et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27(15), 2128-2136 (2008).
98. Grady WM, Parkin RK, Mitchell PS et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27(27), 3880-3888 (2008).
99. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47(11), 939-946 (2008).
100. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 1(12), 882-891 (2003).
101. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl Acad. Sci. USA 104(39), 15472-15477 (2007).
102. Monzo M, Navarro A, Bandres E et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res. 18(8), 823-833 (2008).
103. Landi D, Gemignani F, Naccarati A et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29(3), 579-584 (2008).
104. Nguyen MH, Keeffe EB. Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9. Rev. Gastroenterol Disord. 4(Suppl. 1), S14-S21 (2004).
105. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac. J. Cancer Prev. 5(2), 118-125 (2004).
106. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31(4), 339-346 (2002).
107. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54(4), 533-539 (2005).
108. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J. Gastroenterol. 44(Suppl. 19), 96-101 (2009).
109. Chen S, He Y, Ding J et al. An insertion/deletion polymorphism in the 3′ untranslated region of b-transducin repeat-containing protein (bTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem. Biophys. Res. Commun. 391(1), 552-556 (2010).
110. Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25(17), 2537-2545 (2006).
111. Jiang J, Gusev Y, Aderca I et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 14(2), 419-427 (2008).
112. Gao Y, He Y, Ding J et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1a 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 30(12), 2064-2069 (2009).
113. Apte RN, Voronov E. Is interleukin-1 a good or bad guy in tumor immunobiology and immunotherapy? Immunol. Rev. 222, 222-241 (2008).
114. Busino L, Donzelli M, Chiesa M et al. Degradation of Cdc25A by b-TrCP during S phase and in response to DNA damage. Nature 426(6962), 87-91 (2003).
115. Ougolkov A, Zhang B, Yamashita K et al. Associations among b-TrCP, an E3 ubiquitin ligase receptor, b-catenin, and NF-kB in colorectal cancer. J. Natl Cancer Inst. 96(15), 1161-1170 (2004).
116. Kudo Y, Guardavaccaro D, Santamaria PG et al. Role of F-box protein bTrcp1 in mammary gland development and tumorigenesis. Cell. Mol. Biol. 24(18), 8184-8194 (2004).
117. Koch A, Waha A, Hartmann W et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin. Cancer Res. 11(12), 4295-4304 (2005).
118. miRBase http://microrna.sanger.ac.uk
119. American Cancer Society www.cancer.org